Exagen Inc. (XGN)
Nasdaq · Healthcare · Diagnostics & Research
$8.46+3.55%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $205M
- 52-week range
- $2.59 – $12.23
- 52-week change
- −25.05%
- EPS (trailing)
- −$0.81
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 10, 2026
Fiscal year to Dec 2025
- Revenue
- $66.6M (+19.65%)
- Net income
- −$20.0M
- Operating margin
- −21.1%
- Diluted EPS
- −$0.93
- Free cash flow
- −$14.3M
From the company’s annual report on SEC EDGAR.
About Exagen Inc.
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS.
Headquarters: Vista, United States · 216 employees · exagen.com